drug · small molecule
phentolamine mesylate
Marketedupdated 5mo agoby $IRD Opus Genetics, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for adrenal gland pheochromocytoma and 2 investigational indications.
indications
investigational
Hypertension
targets
Adrenergic receptor alpha
all catalysts(0)
nothing on the calendar yet
Trials studying phentolamine mesylate
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 31, 2034
~7.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (9)
- Dec 25, 2039method-of-use (U-3804)US 12201615
- Oct 25, 2039method-of-use (U-3804)US 11400077
- Oct 25, 2039method-of-use (U-3804)US 12201616
- Jan 31, 2034formulationUS 10278918
- Jan 31, 2034formulationUS 10772829
- Jan 31, 2034formulationUS 11090261
- Jan 31, 2034formulationUS 11844858
- Jan 31, 2034formulationUS 12350366
- Jan 31, 2034formulationUS 9795560
FDA exclusivities (1)
- Sep 25, 2026NPNP
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that